CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.46B, above the global median of $1.18B
- FinancialsAltman Z-Score 9.13: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
3.09%Above 5Y avg (1.65%)
Annual Rate
CNY 0.70Paid annual
Payout Ratio
44.6%Sustainable
Payback Period
32.2 yr
Last Ex-Dividend
Aug 5, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
9.79BCNY1.46B · vs all stocks (USD)
Trailing P/E
16.29xRevenue (TTM)
3.93BCNY586.77M · vs all stocks (USD)
Profit Margin
15.29%Beta
0.2340xvs all stocks
52-Week Change
-15.35%vs all stocks
Market Capitalization
9.79BCNY1.46B · vs all stocks (USD)
Enterprise Value
7.48BCNY1.12B · vs all stocks (USD)
Trailing P/E
16.29xForward P/E
15.30xPrice to Sales (TTM)
2.48xPrice to Book (MRQ)
2.20xEnterprise to Revenue
1.91xEnterprise to EBITDA
10.54xGross Margin
48.20%Profit Margin
15.29%Operating Margin
16.43%Return on Assets (TTM)
7.22%Return on Equity (TTM)
14.16%Revenue (TTM)
3.93BCNY586.77M · vs all stocks (USD)
Revenue per Share (TTM)
9.09CNYUpdated Sep 22, 2026Quarterly Revenue Growth
2.00%Gross Profit (TTM)
1.88BCNY280.26M · vs all stocks (USD)
EBITDA (TTM)
792.91MCNY118.41M · vs all stocks (USD)
Net Income (TTM)
600.88MCNY89.73M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
7.40%Operating Cash Flow (TTM)
720.12MCNY107.54M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
268.30MCNY40.07M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.7000CNYUpdated Sep 22, 2026Trailing Annual Dividend Yield
3.09%vs all stocks
5-Year Average Dividend Yield
1.65%vs all stocks
Payout Ratio
44.60%Minority Interest (Equity)
135.01MCNYFY2025 · Dec 31, 2025Revenue
3.87BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.96BCNYFY2025 · Dec 31, 2025Gross Profit
1.90BCNYFY2025 · Dec 31, 2025Operating Income
669.73MCNY100.01M · vs all stocks (USD)
Pre-tax Income
709.00MCNYFY2025 · Dec 31, 2025Income Tax Expense
103.29MCNYFY2025 · Dec 31, 2025Net Income
605.71MCNYFY2025 · Dec 31, 2025EBIT
716.38MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
823.37MCNYFY2025 · Dec 31, 2025Research & Development
78.11MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
844.71MCNYFY2025 · Dec 31, 2025Other Operating Expenses
31.67MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
40.44MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
7.38MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.35CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.35CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
430.74MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
430.74MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
605.71MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-24.22MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
374.99MCNYFY2025 · Dec 31, 2025Free Cash Flow
256.11MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
2.00BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
605.71MCNYFY2025 · Dec 31, 2025Other Non-cash Items
10.45MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-191.45MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-49.72MCNYFY2025 · Dec 31, 2025Capital Expenditures
-118.87MCNYFY2025 · Dec 31, 2025Net Acquisitions
445.57KCNYFY2025 · Dec 31, 2025Purchase of Investments
-3.78BCNYFY2025 · Dec 31, 2025Sale of Investments
3.04BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-861.72MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
14.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-156.45MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-269.65MCNYFY2025 · Dec 31, 2025Other Financing Charges
-49.60MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-461.70MCNYFY2025 · Dec 31, 2025Shares Outstanding
431.05MSharesUpdated Sep 22, 2026Float Shares
273.01MSharesUpdated Sep 22, 2026% Held by Insiders
35.35%vs all stocks
% Held by Institutions
13.98%vs all stocks
Total Cash (MRQ)
2.51BCNY374.38M · vs all stocks (USD)
Total Cash per Share (MRQ)
5.82CNYUpdated Sep 22, 2026Total Debt (MRQ)
93.48MCNY13.96M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0205xCurrent Ratio (MRQ)
3.52xBook Value per Share (MRQ)
10.30CNYUpdated Sep 22, 2026Total Assets
5.44BCNY811.79M · vs all stocks (USD)
Total Current Assets
3.81BCNYFY2025 · Dec 31, 2025Total Liabilities
921.49MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.63BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
153.84MCNYFY2025 · Dec 31, 2025Total Current Liabilities
767.64MCNYFY2025 · Dec 31, 2025Cash
2.06BCNYFY2025 · Dec 31, 2025Cash Equivalents
28.53MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.09BCNYFY2025 · Dec 31, 2025Other Short-term Investments
506.09MCNYFY2025 · Dec 31, 2025Accounts Receivable
290.99MCNYFY2025 · Dec 31, 2025Inventory
320.87MCNYFY2025 · Dec 31, 2025Accounts Payable
318.20MCNYFY2025 · Dec 31, 2025Short-term Debt
28.81MCNYFY2025 · Dec 31, 2025Other Current Liabilities
34.52MCNYFY2025 · Dec 31, 2025Long-term Debt
70.31MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
6.02MCNYFY2025 · Dec 31, 2025Common Stock (Book)
431.05MCNYFY2025 · Dec 31, 2025Retained Earnings
3.63BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
4.51BCNY674.19M · vs all stocks (USD)
52-Week Low
21.22CNYUpdated Sep 22, 202652-Week High
30.18CNYUpdated Sep 22, 202652-Week Change
-15.35%vs all stocks
Beta
0.2340xvs all stocks
50-Day MA
23.42CNYUpdated Sep 22, 2026200-Day MA
25.33CNYUpdated Sep 22, 2026Avg 10-Day Volume
2.94MSharesUpdated Sep 22, 2026Avg 30-Day Volume
4.02MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
1.39CNYUpdated Sep 22, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 9.13: safe zoneNotable
Altman Z-Score: 9.13
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.46B, above the global median of $1.18BNotable
Market cap (USD): 1,462,469,985.7Global Median: 1,180,223,658.953
Revenue is $586.77M, above the global median of $548.88MNotable
Revenue (USD): 586,766,607.583Global Median: 548,883,780.48
Levered free cash flow is $40.07M, above the global median of $18.73MNotable
Levered free cash flow (USD): 40,065,129.093Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Ningbo Menovo Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Inhibrx Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Taienkang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Omeros Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Classys Inc.
Tier 1ProductionApproval-Gated PipelineRule
Concord Biotech Ltd.
Tier 1ProductionApproval-Gated PipelineRule
D&D Pharmatech Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Maze Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
HBM Holdings Limited
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
KalVista Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Timee Inc.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Beijing Xiaocheng Technology Co. Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Edan Instruments Inc.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities